Eli Lilly, InSilico Strike AI Drug Discovery Deal That Could Be Worth Up to $2.75 Billion
By Jason Chau
Eli Lilly has signed a drug discovery deal with InSilico that the Hong Kong-listed biotech firm says could be valued at as much as $2.75 billion.
The partnership is the latest in a string of tie-ups between pharma majors and Chinese firms, and grants Lilly exclusive worldwide rights to a portfolio of programs across multiple therapeutic areas.
InSilico will receive an upfront payment of $115 million, and is eligible for additional milestone payments that could put the total deal value at about $2.75 billion, it said in a filing.
The companies will also work on multiple research-and-development programs focused on targets selected by Lilly, and using InSilico's Pharma.AI platforms.
Shares of InSilico, which specializes in integrating AI and automation in drug discoveries, surged 10% in early trade on Monday.
Write to Jason Chau at jason.chau@wsj.com
(END) Dow Jones Newswires
March 29, 2026 22:20 ET (02:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

The 10 Best Dividend Stocks

5 Stocks to Buy After Earnings

2 5-Star Stocks to Buy at Big Discounts

Tech Stocks Suffer Worst Week Since 2020 as Anthropic Faces Day Two Decline

